Fibrosis inhibitor for implanted organ
AssigneeKringle Pharma Inc.
InventorsJun Amano, Ken-ichi Ito, Kazuhiro Yamaura, Kunio Matsumoto, Toshikazu Nakamura
Life of this patent
Estimating the term…
Abstract
A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.
Claims1
A method for allowing a recipient patient having a donor organ or tissue transplant to acquire immunologic tolerance to the donor organ or tissue, which comprises administering to the patient an effective amount of hepatocyte growth factor simultaneously with or immediately after the transplantation of the donor organ or tissue,
- wherein the hepatocyte growth factor is a peptide consisting of an amino acid sequence having not less than about 95% homology with SEQ ID NO:
- 2 and which promotes immunological tolerance in the patient.
Dependencies are inferred from the claim text.